Just over a month ago, Financial Times reported that Johnson & Johnson was nearing a deal for Pharmacyclics, a cancer-drug maker. That was before AbbVie apparently swooped in and beat the New Jersey conglomerate by pocketing the company for $21 billion.
The last mega deal Johnson & Johnson did was back in 2012 when it bought orthopedics company Synthes for $19.7 billion.
In its first-quarter conference call with analysts Monday, Johnson & Johnson's CEO - Dominic Caruso - was asked if the company had an appetite for large acquisitions across its different businesses given what's been reported of its involvement in Pharmacyclics.
Help employers find you! Check out all the jobs and post your resume.
The last mega deal Johnson & Johnson did was back in 2012 when it bought orthopedics company Synthes for $19.7 billion.
In its first-quarter conference call with analysts Monday, Johnson & Johnson's CEO - Dominic Caruso - was asked if the company had an appetite for large acquisitions across its different businesses given what's been reported of its involvement in Pharmacyclics.
Help employers find you! Check out all the jobs and post your resume.
